SEPTERNA, INC. COMMON STOCK
NASDAQ: SEPN (Septerna, Inc.)
Last update: yesterday, 4:59PM23.27
4.03 (20.92%)
| Previous Close | 19.24 |
| Open | 19.69 |
| Volume | 1,521,621 |
| Avg. Volume (3M) | 284,864 |
| Market Cap | 1,041,671,552 |
| Price / Earnings (Forward) | 76.92 |
| Price / Sales | 38.99 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -11,831.05% |
| Diluted EPS (TTM) | -1.78 |
| Quarterly Revenue Growth (YOY) | -30.90% |
| Total Debt/Equity (MRQ) | 6.25% |
| Current Ratio (MRQ) | 32.19 |
| Operating Cash Flow (TTM) | -74.10 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -30.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Septerna, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 105.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp V, Llc | 30 Sep 2025 | 6,215,591 |
| Trv Gp Vi, Llc | 30 Sep 2025 | 4,211,659 |
| Checkpoint Capital L.P. | 30 Jun 2025 | 586,473 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 28.95%) | Buy |
| Median | 28.00 (20.35%) | |
| Low | 25.00 (Cantor Fitzgerald, 7.46%) | Buy |
| Average | 27.67 (18.93%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 18.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 14 Nov 2025 | 28.00 (20.35%) | Buy | 23.27 |
| HC Wainwright & Co. | 11 Nov 2025 | 30.00 (28.95%) | Buy | 19.24 |
| 21 Aug 2025 | 26.00 (11.76%) | Buy | 11.70 | |
| Cantor Fitzgerald | 05 Sep 2025 | 25.00 (7.46%) | Buy | 14.43 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Nov 2025 | Announcement | Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Septerna to Participate in Upcoming Investor Conferences |
| 29 Sep 2025 | Announcement | Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors |
| 27 Aug 2025 | Announcement | Septerna to Participate in Upcoming Investor Conferences |
| 21 Aug 2025 | Announcement | Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |